Webinar: Lipid nanoparticle LNP application in gene editing therapies, CRISPR-Cas9

Lipid nanoparticle LNP application in gene editing therapies

Genetic drugs, including small interfering RNA (siRNA), mRNA, or plasmid DNA, hold promise for treating a wide array of diseases by either suppressing harmful genes, producing therapeutic proteins, or employing gene-editing techniques. Currently, lipid nanoparticle (LNP) systems stand at the forefront among non-viral delivery methods, enabling the clinical utilization of genetic drugs.

Gene editing mediated by CRISPR/Cas9 systems is due to become a beneficial therapeutic option for treating genetic diseases and some cancers. Lipid nanoparticles have become an attractive nonviral delivery platform for CRISPR-mediated genome editing due to their low immunogenicity and application flexibility. In this review, we provide a background of CRISPR-mediated gene therapy, as well as LNPs and their applicable characteristics for delivering CRISPR components.

Visit our website for more information.